18 June, 2026
The global scientific community received a significant update today as Clarivate released its 2026 Journal Citation Reports (JCR). For the European Respiratory Society (ERS), the release marks a period of exceptional growth, reinforcing the prestige and influence of its suite of respiratory medicine journals. With the European Respiratory Journal (ERJ) maintaining a dominant position in the global rankings and its sister publications showing marked growth, the ERS continues to solidify its status as a leading voice in pulmonary and critical care research.
Main Facts: A Banner Year for ERS Publications
The 2026 JCR data highlights a consistent upward trajectory across the ERS portfolio. The flagship publication, the European Respiratory Journal (ERJ), remains a titan in the field, securing the number two spot in the Respiratory System category with a formidable Impact Factor of 23.8.
Beyond the flagship, the ERS publishing house has demonstrated broad-spectrum excellence. European Respiratory Review (ERR), a vital source for clinical updates and state-of-the-art reviews, has seen its Impact Factor climb to 10.8. Meanwhile, the society’s open-access and educational outlets have also hit impressive benchmarks: ERJ Open Research has reached an Impact Factor of 4.4, and the clinical educational journal Breathe has ascended to 4.5.
These figures are more than just numerical indicators; they represent the frequency with which research published in these journals is cited by peers, serving as a barometer for the clinical relevance and scientific rigor of the work presented within their pages.
Chronology: The Evolution of ERS Academic Influence
The journey to these 2026 rankings is the result of years of strategic editorial development. To understand the significance of today’s announcement, one must look back at the historical evolution of these publications.
The Foundation of Excellence (2010–2018)
In the early 2010s, the ERS recognized that as the field of respiratory medicine became increasingly specialized, the demand for high-quality, peer-reviewed data would skyrocket. During this period, the European Respiratory Journal began its climb into the top-tier of medical literature, consistently competing with North American-based journals for the highest-quality clinical trials and basic science research.
The Diversification Strategy (2019–2023)
Recognizing that not all research fits the mold of a traditional flagship journal, the ERS launched and nurtured a diverse ecosystem of publications. The decision to bolster ERJ Open Research was a proactive response to the global movement toward open science, ensuring that vital findings—particularly those related to rare diseases and novel interventions—were accessible to researchers worldwide without paywalls. Simultaneously, Breathe was repositioned to serve as a bridge between high-level research and bedside clinical practice, a move that has clearly resonated with the global medical community.
Sustained Momentum (2024–2026)
The period leading up to today’s announcement has been characterized by rigorous editorial standards and an increased focus on digital discoverability. By streamlining the submission process via platforms like Manuscript Central and investing in rapid review cycles, the ERS has attracted high-impact submissions from every continent. The 2026 rankings are the culmination of this systematic effort to modernize the academic publishing workflow.
Supporting Data: Understanding the Impact Factor
The Impact Factor (IF) is a complex metric calculated by Clarivate, reflecting the yearly average number of citations of articles published in the preceding two years. For the scientific community, it is a shorthand for the "weight" of a journal.
| Journal Title | 2026 Impact Factor |
|---|---|
| European Respiratory Journal (ERJ) | 23.8 |
| European Respiratory Review (ERR) | 10.8 |
| Breathe | 4.5 |
| ERJ Open Research | 4.4 |
Analyzing the Trends
The sustained growth of European Respiratory Review to 10.8 is particularly noteworthy. As medical knowledge doubles at an exponential rate, the role of high-quality review articles—which synthesize complex datasets into actionable clinical information—has become paramount. The growth in this specific journal suggests that clinicians and researchers are increasingly turning to the ERS for guidance on navigating the current respiratory landscape.
Furthermore, the rise of Breathe to 4.5 demonstrates the success of the journal’s educational mandate. Unlike traditional journals that focus solely on novel discovery, Breathe focuses on the application of existing knowledge, proving that there is a vast, hungry audience for pedagogical excellence in respiratory medicine.
Official Responses: A Collective Achievement
Following the release of the data, the leadership at the European Respiratory Society expressed profound gratitude to the global medical community. The success of these journals is not merely a product of the editorial offices, but a testament to the symbiotic relationship between authors, reviewers, and editors.
"The 2026 Impact Factor updates reflect the incredible work of our authors and the dedication of our reviewers who uphold the highest standards of scientific integrity," stated a spokesperson for the ERS Editorial Board. "In an era where the speed of information is critical, the fact that our authors continue to entrust their most important findings to ERS publications is a responsibility we do not take lightly. We are honored to serve as the platform for the advancements that are ultimately improving patient care on a global scale."
The ERS has emphasized that while rankings are gratifying, they are viewed primarily as a validation of the community’s shared mission: to promote lung health and alleviate the burden of respiratory disease.
Implications: What This Means for the Future of Respiratory Medicine
The 2026 rankings carry significant implications for the future of the field, impacting everything from clinical practice guidelines to research funding.
Impact on Clinical Practice
High-impact journals are often the source material for international clinical practice guidelines. As the ERJ and ERR continue to set the bar for respiratory research, the findings published within their pages will likely continue to influence the standard of care for conditions ranging from COPD and asthma to interstitial lung disease and post-viral pulmonary complications.
The Open Access Shift
The solid performance of ERJ Open Research signals a pivotal shift in the publishing landscape. As funding agencies increasingly mandate open-access publication for government-funded research, the ERS’s ability to maintain high citation metrics within the open-access model positions the society as a leader in the democratization of medical data.
Attracting Future Talent
For researchers—especially early-career investigators—the prestige of these journals is a major draw. The 2026 rankings will likely lead to an even greater influx of high-quality manuscripts. This creates a "virtuous cycle" where the best research attracts the most citations, which in turn attracts even higher-quality submissions.
The Role of ERS in Global Health
Finally, these rankings reinforce the ERS’s position as a global authority. As respiratory health gains prominence in the wake of recent global health crises, the society’s influence over the academic narrative ensures that respiratory medicine remains a priority on the global research agenda.
Looking Ahead: How to Contribute
As the ERS looks toward the remainder of 2026 and into 2027, the focus remains on maintaining the quality that has led to these stellar metrics. The society is actively encouraging researchers, clinicians, and scientists to submit their work to its family of journals.
The editorial teams are particularly interested in:
- Innovative Clinical Trials: Research that challenges existing paradigms in pulmonary treatment.
- Basic and Translational Science: Studies that bridge the gap between bench-top molecular findings and clinical outcomes.
- Global Health Perspectives: Insights into how respiratory disease is managed in diverse socio-economic and geographic settings.
For those interested in contributing to the continued success of the ERS publishing program, comprehensive submission guidelines and information on the peer-review process are available via the ERS Manuscript Central portal.
In conclusion, the 2026 Clarivate JCR report serves as a milestone, not a destination. It is a moment for the European Respiratory Society to reflect on the hard work of the thousands of individuals who contribute to its mission. With a strong foundation and a clear vision for the future, the ERS is poised to continue leading the way in respiratory medicine, ensuring that science-based insights continue to save lives and improve health outcomes worldwide.
